Cyclodextrin MOFs modified dry powder inhalers quadruple bioavailability of luteolin to ameliorate fibrosing interstitial lung disease
文献类型：期刊论文
| 作者 | Ren, Xiaohong2,3; Yang, Ting1,2; Zhang, Kaikai2; Liu, Yujie2; Wang, Caifen2; Wu, Li2; Zhang, Jiwen2
|
| 刊名 | INTERNATIONAL JOURNAL OF PHARMACEUTICS
 |
| 出版日期 | 2023-10-15 |
| 卷号 | 645页码:9 |
| ISSN号 | 0378-5173 |
| 关键词 | Fibrosing interstitial lung disease Luteolin Cyclodextrin metal -organic frameworks Dry powder inhalers |
| DOI | 10.1016/j.ijpharm.2023.123405 |
| 通讯作者 | Zhang, Jiwen(jwzhang@simm.ac.cn) |
| 英文摘要 | Fibrosing interstitial lung disease (ILD) is a pathological condition that is highly heterogeneous and lethal, and has few effective treatment choices. Other than pirfenidone and nintedanib for the therapy of idiopathic pul-monary fibrosis, no medications are currently licensed for the treatment of ILD. Luteolin is a common flavonoid with multiple biological effects such as anti-inflammation but with poor solubility and absorption. In this study, we loaded luteolin into gamma-cyclodextrin metal-organic frameworks (CD-MOFs) to deliver the medicine to the lungs using dry powder inhalers; in vitro pulmonary deposition results showed LUT@CDMOF had a high fine particle fraction (FPF) (59.77 +/- 3.48%). LUT@CDMOF effectively inhibited ILD progression in the BLM-induced fibrosing ILD model rats. When compared to oral administration, the inhalation of LUT@CDMOF dry powder in rats showed considerable improvements in absorption and bioavailability, with a tmax of 0.08 h and a high absolute bioavailability (82%) of LUT (The AUC(0-t) and Cmax of inhal. LUT@CDMOF respectively increased about 4.03 times and 9.11 times, when compared with the i.g. LUT group). These studies demonstrate the potent anti-inflammatory activities of LUT@CDMOF. The inhaled LUT@CDMOF might be considered as a promising new strategy in the treatment of fibrosing ILD. |
| WOS关键词 | METAL-ORGANIC FRAMEWORKS ; IDIOPATHIC PULMONARY-FIBROSIS ; DRUG ; UPDATE |
| 资助项目 | National Key Research and Development Program of China[2020YFE0201700] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | ELSEVIER |
| WOS记录号 | WOS:001081102100001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/307351]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Zhang, Jiwen |
| 作者单位 | 1.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210046, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Delivery Syst, 501 Haike Rd, Shanghai 201203, Peoples R China 3.Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Taipa 999078, Macao, Peoples R China |
| 推荐引用方式 GB/T 7714 | Ren, Xiaohong,Yang, Ting,Zhang, Kaikai,et al. Cyclodextrin MOFs modified dry powder inhalers quadruple bioavailability of luteolin to ameliorate fibrosing interstitial lung disease[J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS,2023,645:9. |
| APA | Ren, Xiaohong.,Yang, Ting.,Zhang, Kaikai.,Liu, Yujie.,Wang, Caifen.,...&Zhang, Jiwen.(2023).Cyclodextrin MOFs modified dry powder inhalers quadruple bioavailability of luteolin to ameliorate fibrosing interstitial lung disease.INTERNATIONAL JOURNAL OF PHARMACEUTICS,645,9. |
| MLA | Ren, Xiaohong,et al."Cyclodextrin MOFs modified dry powder inhalers quadruple bioavailability of luteolin to ameliorate fibrosing interstitial lung disease".INTERNATIONAL JOURNAL OF PHARMACEUTICS 645(2023):9. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。